M. S. Rajkovic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
M. S. Rajkovic has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Mukhammad A. Sayfullin
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
4 shared publications - A. L. Rossina
Pirogov Russian National Research Medical University
3 shared publications - A. N. Slatetskaya
Russian Children's Clinical Hospital — Branch of N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
3 shared publications - Elena Efimovna Petryaykina
Pirogov Russian National Research Medical University
3 shared publications - Olga V. Shamsheva
Pirogov Russian National Research Medical University
3 shared publications - S. B. Chuyelov
Pirogov Russian National Research Medical University
3 shared publications
Latest Publications
- Open Access
- 25 June 2025
- Published by Journal of Childrens Infections in CHILDREN INFECTIONS
- Vol. 24 (2) , 10-15
Serological Profile of COVID-19 in Children with Comorbidities during Omicron Variant Circulation
Тhe characteristics of the humoral immune response to SARS-CoV-2 in children, particularly those with comorbid conditions, remain incompletely understood. The observed variability in antibody production and the sensitivity of serological assays complicate the objective assessment of seroconversion in the pediatric population.Objective: To determine the qualitative and quantitative profiles of IgM and IgG antibodies against SARS-CoV-2 in children with somatic comorbidities during the acute phase of COVID-19 amid the circulation of the Omicron variant.Materials and Methods: A prospective, single-center, non-randomized cohort study was conducted involving hospitalized children with confirmed COVID-19 and underlying chronic conditions. Serological testing was performed on days 1, 8, and 14 of illness using enzyme-linked immunosorbent assay (ELISA) and immunochemiluminescence assay (ICLA) to measure IgM and IgG levels.Results: A total of 99 children with comorbidities were included in the analysis. The seropositivity rate for IgM remained low at all time points (up to 26.3% on day 14). IgG antibodies were detected in the majority of patients as early as day 1, with ELISA demonstrating higher sensitivity (77.6%) compared to ICLA (60%), peak IgG levels were observed on day 8, followed by a significant decline by day 14 (p < 0.01). Children with respiratory system diseases exhibited statistically higher IgG levels compared to those with hemoblastoses, solid tumors, primary immunodeficiencies, and nervous system disorders.Conclusions: Serological diagnosis of COVID-19 in children with comorbidities requires careful consideration of the testing method, disease timeline, and type of underlying somatic pathology. IgG antibodies serve as a more informative marker than IgM, with ELISA offering superior sensitivity.
- 25 June 2025
- Published by Journal of Childrens Infections in CHILDREN INFECTIONS
- Vol. 24 (2) , 10-15
Open AccessSerological Profile of COVID-19 in Children with Comorbidities during Omicron Variant Circulation
Тhe characteristics of the humoral immune response to SARS-CoV-2 in children, particularly those with comorbid conditions, remain incompletely understood. The observed variability in antibody production and the sensitivity of serological assays complicate the objective assessment of seroconversion in the pediatric population.Objective: To determine the qualitative and quantitative profiles of IgM and IgG antibodies against SARS-CoV-2 in children with somatic comorbidities during the acute phase of COVID-19 amid the circulation of the Omicron variant.Materials and Methods: A prospective, single-center, non-randomized cohort study was conducted involving hospitalized children with confirmed COVID-19 and underlying chronic conditions. Serological testing was performed on days 1, 8, and 14 of illness using enzyme-linked immunosorbent assay (ELISA) and immunochemiluminescence assay (ICLA) to measure IgM and IgG levels.Results: A total of 99 children with comorbidities were included in the analysis. The seropositivity rate for IgM remained low at all time points (up to 26.3% on day 14). IgG antibodies were detected in the majority of patients as early as day 1, with ELISA demonstrating higher sensitivity (77.6%) compared to ICLA (60%), peak IgG levels were observed on day 8, followed by a significant decline by day 14 (p < 0.01). Children with respiratory system diseases exhibited statistically higher IgG levels compared to those with hemoblastoses, solid tumors, primary immunodeficiencies, and nervous system disorders.Conclusions: Serological diagnosis of COVID-19 in children with comorbidities requires careful consideration of the testing method, disease timeline, and type of underlying somatic pathology. IgG antibodies serve as a more informative marker than IgM, with ELISA offering superior sensitivity.
- Open Access
- 17 January 2025
- Published by LLC Global Media Technology in Experimental and Clinical Gastroenterology
- No. 1,p. 21-31
COVID-19 in children with chronic digestive system pathology
COVID-19 in children is characterized by a predominance of mild and asymptomatic forms, along with frequent gastrointestinal symptoms. It is known that comorbid conditions are a risk factor for severe COVID-19 in children; however, the course of SARS-CoV-2 infection in children with chronic digestive system diseases remains under-researched. Objective. To identify the specific characteristics of COVID-19 in children with chronic digestive system diseases, assess risk factors for severe COVID-19, and evaluate the impact of immunosuppressive therapy on COVID-19 outcomes. Materials and Methods. A single-center cohort retrospective and prospective non-randomized study was conducted, including 74 patients with COVID-19 and chronic digestive system diseases and a control group of 30 patients with COVID-19 without comorbidities, all hospitalized in the infectious disease department of the Russian Children’s Clinical Hospital, Moscow, in 2022 and 2023. Results. Сhildren with underlying digestive system diseases were not at a higher risk of severe COVID-19 compared to the control group. Severe, uncontrolled somatic disease and the presence of two or more comorbidities were risk factors for complicated SARS-CoV-2 infection. The duration of detectable SARS-CoV-2 RNA in the study group was nine days. Conclusion. Patients with chronic digestive system diseases, including those receiving immunosuppressive therapy, do not appear to be at higher risk for severe or unfavorable COVID-19 outcomes; however, prolonged SARS-CoV-2 RNA shedding was observed. Risk factors for severe COVID-19 include the presence of two or more comorbidities and severe somatic disease.
- 17 January 2025
- Published by LLC Global Media Technology in Experimental and Clinical Gastroenterology
- No. 1,p. 21-31
Open AccessCOVID-19 in children with chronic digestive system pathology
COVID-19 in children is characterized by a predominance of mild and asymptomatic forms, along with frequent gastrointestinal symptoms. It is known that comorbid conditions are a risk factor for severe COVID-19 in children; however, the course of SARS-CoV-2 infection in children with chronic digestive system diseases remains under-researched. Objective. To identify the specific characteristics of COVID-19 in children with chronic digestive system diseases, assess risk factors for severe COVID-19, and evaluate the impact of immunosuppressive therapy on COVID-19 outcomes. Materials and Methods. A single-center cohort retrospective and prospective non-randomized study was conducted, including 74 patients with COVID-19 and chronic digestive system diseases and a control group of 30 patients with COVID-19 without comorbidities, all hospitalized in the infectious disease department of the Russian Children’s Clinical Hospital, Moscow, in 2022 and 2023. Results. Сhildren with underlying digestive system diseases were not at a higher risk of severe COVID-19 compared to the control group. Severe, uncontrolled somatic disease and the presence of two or more comorbidities were risk factors for complicated SARS-CoV-2 infection. The duration of detectable SARS-CoV-2 RNA in the study group was nine days. Conclusion. Patients with chronic digestive system diseases, including those receiving immunosuppressive therapy, do not appear to be at higher risk for severe or unfavorable COVID-19 outcomes; however, prolonged SARS-CoV-2 RNA shedding was observed. Risk factors for severe COVID-19 include the presence of two or more comorbidities and severe somatic disease.
- Open Access
- 16 November 2024
- Published by Journal of Childrens Infections in CHILDREN INFECTIONS
- Vol. 23 (4) , 22-28
COVID-19 in children with somatic pathology
The coronavirus infection is a pressing issue in modern healthcare, yet the characteristics of the SARS-CoV-2 infection course in children with comorbidities remain insufficiently studied. The aim of this study was to evaluate the clinical form, severity, and duration of SARS-CoV-2 virus shedding in pediatric patients with somatic diseases, depending on the comorbid pathology. Materials and Methods. A comprehensive single-center retrospective study was conducted, analyzing 314 medical records of patients hospitalized in the infectious diseases department of the Russian Children’s Clinical Hospital in Moscow over 11 months in 2022. The inclusion criterion was the presence of a laboratory-confirmed COVID-19 diagnosis. Results. Children with comorbidities were found to be predisposed to a more severe course of SARS-CoV-2 infection compared to the pediatric population in general. Children with hematological diseases were at the highest risk of adverse outcomes from COVID-19. Patients with oncological and hematological diseases and primary immunodeficiencies shed the SARS-CoV-2 virus significantly longer than patients with other somatic pathologies. The duration of SARS-CoV-2 RNA detection in patients with severe COVID-19 was significantly longer, which also correlated with the severity of the underlying somatic disease. Conclusion. Children with comorbidities are at risk for a more severe and prolonged course of SARS-CoV-2 infection.
- 16 November 2024
- Published by Journal of Childrens Infections in CHILDREN INFECTIONS
- Vol. 23 (4) , 22-28
Open AccessCOVID-19 in children with somatic pathology
The coronavirus infection is a pressing issue in modern healthcare, yet the characteristics of the SARS-CoV-2 infection course in children with comorbidities remain insufficiently studied. The aim of this study was to evaluate the clinical form, severity, and duration of SARS-CoV-2 virus shedding in pediatric patients with somatic diseases, depending on the comorbid pathology. Materials and Methods. A comprehensive single-center retrospective study was conducted, analyzing 314 medical records of patients hospitalized in the infectious diseases department of the Russian Children’s Clinical Hospital in Moscow over 11 months in 2022. The inclusion criterion was the presence of a laboratory-confirmed COVID-19 diagnosis. Results. Children with comorbidities were found to be predisposed to a more severe course of SARS-CoV-2 infection compared to the pediatric population in general. Children with hematological diseases were at the highest risk of adverse outcomes from COVID-19. Patients with oncological and hematological diseases and primary immunodeficiencies shed the SARS-CoV-2 virus significantly longer than patients with other somatic pathologies. The duration of SARS-CoV-2 RNA detection in patients with severe COVID-19 was significantly longer, which also correlated with the severity of the underlying somatic disease. Conclusion. Children with comorbidities are at risk for a more severe and prolonged course of SARS-CoV-2 infection.
- 1 January 2021
- Published by Geotar-Media Publishing Group in Infectious diseases: News, Opinions, Training
- Vol. 3 (38)
Chickenpox in pregnant women in Moscow 2009–2019
- 1 January 2021
- Published by Geotar-Media Publishing Group in Infectious diseases: News, Opinions, Training
- Vol. 3 (38)
Chickenpox in pregnant women in Moscow 2009–2019